XV. 8 Profile 8: Parkinson's Disease
In Parkinson's disease FMT is investigational: the two randomised trials contradict each other, no motor benefit is established, and gastrointestinal adverse events were markedly more frequent in the FMT arm – it does not replace standard therapy.
| Parameter | Parkinson's-specific detail |
|---|---|
| Evidence level | ★★☆☆☆ Early-stage. Observational studies and small pilot trials demonstrating gut microbiota dysbiosis precedes motor symptoms by years. Two phase 2 randomised, placebo-controlled FMT trials have been completed (GUT-PARFECT 2024; Scheperjans et al. 2024) with contradictory results; no large confirmatory RCT exists. FMT for Parkinson's is investigational. |
| Mechanism of dysbiosis | Alpha-synuclein aggregation may originate in enteric nervous system (Braak hypothesis: gut-to-brain propagation via vagus nerve). Reduced SCFA producers (Prevotellaceae, Lachnospiraceae); elevated pro-inflammatory Proteobacteria; impaired mucosal barrier with systemic LPS leak driving neuroinflammation. |
| Primary microbiota targets | Restore Prevotella copri and short-chain fatty acid producers. Reduce Proteobacteria-driven LPS load. Support mucosal barrier integrity. Modulate enteric immune tone to reduce alpha-synuclein seeding conditions. |
| Protocol modification | Full 4-phase protocol with extended Phase 2 consolidation (minimum 90 days). Neurological monitoring required alongside GI monitoring. Coordination with treating neurologist essential. Dopaminergic medication timing relative to FMT capsule dosing should be optimised to avoid absorption interference. |
| Minimum transfer duration | 90 days minimum. Neurological outcomes require sustained ecological remodelling. Gut–brain axis modulation occurs over months, not weeks. Some protocols evaluate 12-month continuous low-dose maintenance. |
| Priority exposome focus | Physical exercise (directly improves gut motility and microbiota diversity; independently protective in Parkinson's). High-fiber, low-processed food diet. Circadian rhythm regulation (Parkinson's patients have severe circadian disruption compounding dysbiosis). Stress management (HPA axis-enteric nervous system crosstalk). Constipation management – critical, as constipation is both symptom and amplifier of dysbiosis. |
| Expected response timeline | GI symptoms (constipation, bloating): improvement within 4–8 weeks. Neuroinflammatory markers: 3–6 months. Motor symptoms: not established as FMT primary endpoint; any motor changes should be documented but interpreted cautiously. Quality of life and non-motor symptoms may improve before motor signs. |
| Warning signs (Parkinson's-specific) | Sudden worsening of motor function or rigidity after FMT initiation (may indicate inflammatory response). Severe aspiration risk during capsule administration in patients with dysphagia – swallowing assessment required before capsule protocol. Unexplained confusion or altered mental status. Significant orthostatic hypotension worsening post-FMT. |
Table 19 – Clinical profile: Parkinson's Disease # Protocol parameters, evidence level, and clinical modifications specific to Parkinson's disease.
Note: FMT in Parkinson's disease is investigational. All treatment decisions must be made in conjunction with the patient's neurologist. Constipation management and physical activity are co-primary non-pharmacological interventions.
Two randomised, placebo-controlled FMT trials have been reported in Parkinson's disease, and they contradict each other. In the Belgian GUT-PARFECT trial (double-blind, placebo-controlled, phase 2; n=46, aged 50–65, mild to moderate disease), a single nasojejunal FMT was followed at 12 months by a mean 5.8-point improvement in the MDS-UPDRS motor score, versus 2.7 points in the placebo arm (p=0.0235); the roughly 3-point difference sits at the very edge of clinical relevance, and relief of constipation preceded the motor change [743]. The Finnish four-centre trial (Scheperjans et al., JAMA Neurology 2024; 48 patients randomised, Hoehn–Yahr 1–3), by contrast, found no difference on the primary endpoint: the between-group difference in the change of MDS-UPDRS parts I–III at 6 months was 0.97 points (95% CI −5.10 to 7.03; p=0.75). In the same trial, gastrointestinal adverse events were substantially more frequent in the FMT arm (53% vs 7%; p=0.003), and several secondary outcomes – including the trajectory of dopaminergic medication requirements – favoured placebo [744]. In summary: a motor benefit of FMT in Parkinson's disease is not established, and the procedure is not free of adverse effects. A mechanistic review builds the clinical-trial design framework around the vagal–microbiome–alpha-synuclein axis [725].
Clinical Implications
- A motor effect of FMT in Parkinson's disease has not been demonstrated – the two randomised trials produced opposite results, and the trial with the stricter, prespecified primary endpoint was negative. FMT must not be presented as a proven motor therapy in Parkinson's disease.
- Safety requires separate consideration: in the Finnish trial more than half of the FMT arm experienced gastrointestinal adverse events, against 7% on placebo. Patient information must state this.
- If FMT has any role at all, it is likely an early-stage indication – in advanced Parkinson's (stages 3–5) CNS pathology is so established that little can be expected from a peripheral (gut) intervention. This is a hypothesis, however, not a difference demonstrated in a trial.
- Premorbid/prodromal Parkinson's (RBD, hyposmia, chronic constipation) may represent an interesting preventive window – but prospective evidence is lacking.
- Vagal–microbiome axis: enteric alpha-synuclein aggregation may be transported to the CNS via the vagus nerve. Interrupting this is the presumed central mechanism of peripheral interventions – no human trial has confirmed it to date [725].
Clinical Practice Recommendations
- FMT in Parkinson's disease is investigational and belongs solely within a clinical trial protocol – it cannot replace classical dopaminergic therapy, and on current evidence it must not be offered with the promise of motor improvement.
- Concomitant chronic constipation in Parkinson patients is clinically important and warrants standalone treatment – here microbiome support (fibre, prebiotics, regular exercise) is an evidence-based adjuvant; gut-related improvement was the most consistent signal in both randomised trials.
- Donor portrait: available human data are insufficient to define an "ideal" donor profile (for example enrichment of butyrate-producing taxa or Akkermansia muciniphila). In the Finnish trial microbiota change differed by donor, without clinical benefit.
References
[725] dos Santos JCC, Oliveira LF, Noleto FM, et al. Gut-microbiome-brain axis: the crosstalk between the vagus nerve, alpha-synuclein and the brain in Parkinson's disease. . 2023. Link
Review article: the gut-microbiome-brain axis in Parkinson's disease — enteric alpha-synuclein aggregation may propagate via the vagus nerve to the CNS, with microbiota metabolites signaling through vagal afferents; a mechanistic synthesis relevant to peripheral intervention targets.
[743] Bruggeman A, Vandendriessche C, Hamerlinck H, De Looze D, Tate DJ, Vuylsteke M, De Commer L, Devolder L, Raes J, Verhasselt B, Laukens D, Vandenbroucke RE, Santens P. Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson's disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial. eClinicalMedicine. 2024. Link
Double-blind, placebo-controlled, randomised phase 2 trial (Ghent, n=46, aged 50–65, mild to moderate Parkinson's disease): after a single nasojejunal healthy-donor FMT the MDS-UPDRS motor score improved by a mean of 5.8 points at 12 months versus 2.7 points on placebo (autologous stool) (p=0.0235). The difference sits at the edge of clinical relevance and emerged mainly between months 6 and 12. Relief of constipation preceded the motor change. No serious FMT-related adverse events occurred; transient abdominal discomfort did.
[744] Scheperjans F, Levo R, Bosch B, Lääperi M, Pereira PAB, Smolander OP, Aho VTE, Vetkas N, Toivio L, Kainulainen V, Fedorova TD, Lahtinen P, Ortiz R, Kaasinen V, Satokari R, Arkkila P. Fecal Microbiota Transplantation for Treatment of Parkinson Disease: A Randomized Clinical Trial. JAMA Neurology. 2024. Link
NEGATIVE trial. Double-blind, placebo-controlled randomised clinical trial at four Finnish hospitals (48 randomised, 45 in the intention-to-treat analysis; aged 35–75, Hoehn & Yahr 1–3, with documented faecal dysbiosis), single-dose colonic anaerobically prepared FMT versus placebo in a 2:1 ratio. The primary endpoint – change in MDS-UPDRS parts I–III at 6 months – did not differ between groups (0.97 points; 95% CI −5.10 to 7.03; P = .75). Gastrointestinal adverse events were markedly more frequent in the FMT arm (16 [53%] vs 1 [7%]; P = .003). Increases in dopaminergic medication and improvement in several motor and non-motor secondary outcomes were stronger in the placebo group. Microbiota changes were more pronounced after FMT but differed by donor; nevertheless dysbiosis status reversed more often on placebo. Conclusion: FMT was safe but did not offer clinically meaningful improvement.